274 related articles for article (PubMed ID: 30005689)
1. Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS).
Sergeant JC; Hyrich KL; Anderson J; Kopec-Harding K; Hope HF; Symmons DPM; ; Barton A; Verstappen SMM
Arthritis Res Ther; 2018 Jul; 20(1):147. PubMed ID: 30005689
[TBL] [Abstract][Full Text] [Related]
2. The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate.
Hope HF; Hyrich KL; Anderson J; Bluett J; Sergeant JC; Barton A; Cordingley L; Verstappen SMM;
Rheumatology (Oxford); 2020 Jan; 59(1):213-223. PubMed ID: 31302692
[TBL] [Abstract][Full Text] [Related]
3. Current smoking predicts inadequate response to methotrexate monotherapy in rheumatoid arthritis patients naïve to DMARDs: Results from a retrospective cohort study.
Floris A; Perra D; Cangemi I; Congia M; Chessa E; Angioni MM; Mangoni AA; Erre GL; Mathieu A; Piga M; Cauli A
Medicine (Baltimore); 2021 Apr; 100(17):e25481. PubMed ID: 33907096
[TBL] [Abstract][Full Text] [Related]
4. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.
Barrera P; van der Maas A; van Ede AE; Kiemeney BA; Laan RF; van de Putte LB; van Riel PL
Rheumatology (Oxford); 2002 Apr; 41(4):430-9. PubMed ID: 11961174
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-132, miR-146a, and miR-155 as potential biomarkers of methotrexate response in patients with rheumatoid arthritis.
Singh A; Patro PS; Aggarwal A
Clin Rheumatol; 2019 Mar; 38(3):877-884. PubMed ID: 30511295
[TBL] [Abstract][Full Text] [Related]
6. Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis?
Hider SL; Silman AJ; Thomson W; Lunt M; Bunn D; Symmons DP
Ann Rheum Dis; 2009 Jan; 68(1):57-62. PubMed ID: 18292102
[TBL] [Abstract][Full Text] [Related]
7. Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis.
Plant D; Maciejewski M; Smith S; Nair N; ; Hyrich K; Ziemek D; Barton A; Verstappen S
Arthritis Rheumatol; 2019 May; 71(5):678-684. PubMed ID: 30615300
[TBL] [Abstract][Full Text] [Related]
8. Good response to methotrexate is associated with a decrease in the gene expression of ABCG2, a drug transporter, in patients with rheumatoid arthritis.
Muto S; Minamitani N; Ogura T; Nakajima A; Nakagawa K; Masaka T; Hiura S; Kobayashi H; Kato H; Kameda H
Mod Rheumatol; 2021 Nov; 31(6):1079-1086. PubMed ID: 33492182
[TBL] [Abstract][Full Text] [Related]
9. CD39 positive regulatory T cell frequency as a biomarker of treatment response to methotrexate in rheumatoid arthritis.
Gupta V; Katiyar S; Singh A; Misra R; Aggarwal A
Int J Rheum Dis; 2018 Aug; 21(8):1548-1556. PubMed ID: 30146748
[TBL] [Abstract][Full Text] [Related]
10. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors.
Martínez-Feito A; Plasencia-Rodríguez C; Navarro-Compán V; Hernández-Breijo B; González MÁ; Monjo I; Nuño L; Nozal P; Pascual-Salcedo D; Balsa A
Clin Rheumatol; 2019 Mar; 38(3):949-954. PubMed ID: 30402698
[TBL] [Abstract][Full Text] [Related]
11. Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study.
Aramaki T; Ueki Y; Kojima K; Kurushima S; Tsuji Y; Kawachi N; Iwamoto N; Ichinose K; Terada K; Eguchi K; Kawakami A
Mod Rheumatol; 2020 Jan; 30(1):50-57. PubMed ID: 30482075
[No Abstract] [Full Text] [Related]
12. Identification of gene expression biomarkers to predict clinical response to methotrexate in patients with rheumatoid arthritis.
Palmowski A; Strehl C; Pfeiffenberger M; Häupl T; Schad M; Kallarackal J; Prothmann U; Dammann D; Bonin M; Brandt A; Schneider U; Gaber T; Buttgereit F
Clin Rheumatol; 2024 Jan; 43(1):511-519. PubMed ID: 37978145
[TBL] [Abstract][Full Text] [Related]
13. Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis.
Gwinnutt JM; Leggett S; Lunt M; Barton A; Hyrich KL; Walker-Bone K; Verstappen SMM;
Rheumatology (Oxford); 2020 Oct; 59(10):2908-2919. PubMed ID: 32097471
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a prognostic multivariable model to predict insufficient clinical response to methotrexate in rheumatoid arthritis.
de Rotte MCFJ; Pluijm SMF; de Jong PHP; Bulatović Ćalasan M; Wulffraat NM; Weel AEAM; Lindemans J; Hazes JMW; de Jonge R
PLoS One; 2018; 13(12):e0208534. PubMed ID: 30532219
[TBL] [Abstract][Full Text] [Related]
15. Predictors of response to etanercept-methotrexate treatment: a post hoc logistic regression analysis of a randomized, open-label study in Latin American patients with rheumatoid arthritis.
de la Vega M; Guerra Bautista G; Xavier RM; Pacheco-Tena C; Solano G; Pedersen RD; Szumski AE; Borlenghi C; Santana K; Vlahos B
Adv Rheumatol; 2021 Sep; 61(1):56. PubMed ID: 34496979
[TBL] [Abstract][Full Text] [Related]
16. Polymorphism of genes involved in methotrexate pathway: Predictors of response to methotrexate therapy in Indian rheumatoid arthritis patients.
Singh A; Gangadharan H; Gupta V; Patro PS; Misra R; Aggarwal A
Int J Rheum Dis; 2021 May; 24(5):654-662. PubMed ID: 33780152
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
Müller RB; von Kempis J; Haile SR; Schiff MH
Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
[TBL] [Abstract][Full Text] [Related]
18. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial.
Kameda H; Ueki Y; Saito K; Nagaoka S; Hidaka T; Atsumi T; Tsukano M; Kasama T; Shiozawa S; Tanaka Y; Takeuchi T;
Mod Rheumatol; 2010 Dec; 20(6):531-8. PubMed ID: 20574649
[TBL] [Abstract][Full Text] [Related]
19. High serum level of haptoglobin is associated with the response of 12 weeks methotrexate therapy in recent-onset rheumatoid arthritis patients.
Tan W; Wang F; Guo D; Ke Y; Shen Y; Lv C; Zhang M
Int J Rheum Dis; 2016 May; 19(5):482-9. PubMed ID: 24863583
[TBL] [Abstract][Full Text] [Related]
20. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
Mary J; De Bandt M; Lukas C; Morel J; Combe B
J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
